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Leading Edge
EssayLife expectancy has increased steadily 
over the last century and almost doubled 
in many countries and cultures. This 
increase is not due to an intrinsic change 
in human physiology but reflects large-
scale improvements in public health. 
The major cause of mortality is shift-
ing rapidly from infectious diseases to 
a variety of cardiovascular and meta-
bolic disorders. Although treating dia-
betes, hypertension, or hyperlipidemia 
generally increases life span, there is 
no evidence that global application of 
drug interventions (e.g., statins for heart 
disease) improves longevity in healthy 
subjects. Here, we do not consider path-
ways that cause either rare (e.g., prog-
eria) or common (e.g., hypertension or 
hyperlipidemia) diseases. Instead we 
focus on molecular and cellular networks 
that are part of an intrinsic program that 
controls life span in the absence of overt 
disease.
The only intervention that consistently 
has been shown to increase life span 
from nematodes to primates is caloric or 
dietary restriction (Colman et al., 2009; 
Fontana et al., 2010; Lin et al., 2002). How 
caloric restriction (CR) extends life span 
is still not well understood (reviewed in 
Canto and Auwerx, 2009), but several 
studies demonstrate that perception 
and sensing of nutrient levels is impor-
tant. It is likely that the absence of spe-
cific dietary amino acids mediates the 
effects of CR rather than the restriction 
of calorie intake per se (Grandison et al., 
2009; Miller et al., 2005). A diet low in the 
essential amino acid methionine boosts 
life span in the mouse and reduces age-
related pathologies (Miller et al., 2005). 
Addition of methionine alone to a CR 
diet also averts the reduced fecundity 
normally associated with CR in the fruit 
fly Drosophila melanogaster but without 
affecting increased longevity (Grandi-
son et al., 2009). Surprisingly, whereas 
addition of essential amino acids to a 
CR diet reduced life span, this reduc-
tion in life span could be prevented 
by simply removing methionine from 
the diet, indicating that the interaction 
between methionine and other amino 
acids plays a key role (Grandison et al., 
2009). Mechanisms directly linked to 
methionine manipulation are unknown 
but may involve specific metabolic 
sensors, many of which are extremely 
well conserved and often act in a cell-
autonomous fashion (that is, within the 
cell). Possible sensors include the tar-
get of rapamycin (TOR), AMP-activated 
protein kinase (AMPK), and the sirtuin 
proteins that detect changes in specific 
metabolites such as amino acids, AMP, 
and NAD+, respectively. Such changes, 
reflecting the general metabolic state, 
could trigger metabolic adaptations, 
possibly through regulators such as 
the forkhead box transcription factors 
(including the FOXO and FOXA families), 
SMK-1 (suppressor of MEK null), and the 
peroxisome proliferator-activated recep-
tor γ coactivator 1α (PGC-1α).
Interestingly, the sensory percep-
tion of nutrients is also involved in CR-
induced longevity. This suggests that 
non-cell-autonomous signaling (relying 
on external cues, such as hormonal and 
neuronal pathways) also may be involved 
in the aging process (reviewed in Libert 
and Pletcher, 2007). Blocking sensory 
perception in the nematode Caenorhab-
ditis elegans or D. melanogaster by 
ablation of the chemosensory neurons 
or by deletion of the odorant receptor 
Or83b, respectively, increases life span. 
Although CR still extends life span in the 
Or83b mutant flies, the effect was milder 
than in wild-type flies. Strikingly, even 
exposure to food odorants dampens the 
CR-induced life-span extension in flies 
(Libert and Pletcher, 2007). The fact that 
serotonin inhibitors, which in humans 
are used as antidepressants and often 
induce weight loss, also extend life span 
in C. elegans (Libert and Pletcher, 2007) 
suggests that specific neuronal signaling 
pathways may mimic the pseudostarved 
state. Whether and how sensory percep-
tion is also relevant in mammals merits 
further research.
Elucidating the mechanisms by which 
both these cell-autonomous and non-
cell-autonomous signaling pathways 
are integrated to control the response 
to CR will be key for understanding lon-
gevity and its natural variation. How-
ever, the beneficial effects of CR are not 
uniformly mediated by these pathways 
because their actions depend largely on 
the context of the CR regimen and the 
compensatory regulatory networks that 
are activated. It is therefore no surprise 
that depending on the timing and type 
of the CR, certain genes and pathways 
are dispensable for the effect on life 
span (Kenyon, 2010). How these various 
signaling pathways impact longevity, 
whether CR-induced or natural, is still 
not clear.
Longevity Genes and Metabolic 
Pathways
The insulin/IGF1 signaling pathway is the 
best characterized pathway affecting 
longevity (Figure 1). In C. elegans and D. 
melanogaster—organisms in which the 
insulin and IGF1 pathways converge on 
Metabolic Networks of Longevity
Riekelt H. Houtkooper,1 Robert W. Williams,2 and Johan Auwerx1,*
1Laboratory for Integrative and Systems Physiology, Ecole Polytechnique Fédérale de Lausanne, Lausanne 1015, Switzerland
2Department of Anatomy and Neurobiology and Center for Integrative and Translational Genomics, Memphis, TN 38163, USA
*Correspondence: johan.auwerx@epfl.ch
DOI 10.1016/j.cell.2010.06.029
Molecular and cellular networks implicated in aging depend on a multitude of proteins that collec-
tively mount adaptive and contingent metabolic responses to environmental challenges. Here, we 
discuss the intimate links between metabolic regulation and longevity and outline new approaches 
for analyzing and manipulating such links to promote human health span.Cell 142, July 9, 2010 ©2010 Elsevier Inc. 9
a single receptor—decreased insulin/
IGF1 signaling increases life span by 
as much as 2-fold (reviewed in Kenyon, 
2010). In mammals, the role of the insu-
lin/IGF1 signaling network in longevity is 
complicated by potential involvement of 
multiple insulin/IGF receptors. Perturb-
ing this pathway in mice results in severe 
metabolic disease leading to premature 
death (reviewed in Russell and Kahn, 
2007). Several studies, however, have 
connected insulin/IGF1 signaling to lon-
gevity in mammals. Life span is clearly 
increased by heterozygous and tissue-
specific mutations in components of 
the insulin/IGF1 pathway (Russell and 
Kahn, 2007). The FOXO (forkhead box) 
transcription factors are key modulators 
of this insulin/IGF1 network (Kenyon, 
2010). Phosphorylation of FOXO by 
AKT—a downstream kinase in the insu-
lin/IGF1 pathway—results in transloca-
tion of FOXO to the cytosol and inactiva-
tion of its pro-longevity transcriptional 
targets. Such targets include genes 
involved in defense against oxidative 
stress and genes encoding molecular 
chaperones (Russell and Kahn, 2007). 
Consistent with this, deleting daf-16 (the 
C. elegans FOXO homolog) in worms 
carrying a mutated daf2 (which have 
no insulin/IGF1 signaling) abrogates the 
life-span extension of the daf2 mutant 
worms (Kenyon, 2010). The importance 
of FOXO in CR-induced longevity is, 
however, still under debate. In contrast 
to worm daf-16, the PHA-4 protein of 
C. elegans, which is homologous to the 
mammalian family of Foxa transcrip-
tion factors, mediates the effects of CR 
on life span but is not required for the 
increased longevity caused by other 
genetic pathways that regulate aging 
(Panowski et al., 2007). Future research 
will need to address what causes these 
species-specific differences and how 
such differences can be used to influ-
ence mammalian longevity.
The TOR signaling pathway is also 
a critical player in longevity. Initially 
characterized for its involvement in the 
antifungal effects of the drug rapamy-
cin, TOR proteins are now recognized 
as sensors that link nutrient availability 
to cellular growth (reviewed in Stanfel 
et al., 2009). In yeast, worms, and flies, 
manipulation of TOR by genetic ablation 
or by pharmacological inhibition using 
rapamycin greatly improves life span 
(Figure 1) (Stanfel et al., 2009). The same 
beneficial effect of rapamycin was also 
seen in mice, where it increased mean 
and maximum life span, even though the 
animals were already old when treatment 
began (Harrison et al., 2009). Using vari-
ous fly mutants, the effects of rapamy-
cin on longevity have been linked to the 
regulatory role of TOR on autophagy 
and on translation. The ribosomal S6 
protein kinase 1 (S6K1) and the eukary-
otic translation initiation factor 4E bind-
ing protein (4E-BP), both downstream 
effectors of TOR, are critically involved 
in these processes (Bjedov et al., 2010). 
The role of autophagy in longevity has 
been further substantiated by using the 
polyamine spermidine, a compound 
that induces autophagy, inhibits oxida-
tive stress, and increases life span in 
several model organisms (Eisenberg et 
al., 2009). Finally, the roles of S6K1 and 
4E-BP in life-span extension have been 
confirmed in genetic models. Deletion 
of 4E-BP in D. melanogaster decreases 
life span and abrogates CR-induced 
longevity, whereas overexpression of 
4E-BP does not enhance the effect of 
CR, suggesting that 4E-BP is crucial for 
CR-induced longevity (Zid et al., 2009). 
Conversely, female mice lacking S6K1 
live longer, healthier lives compared 
with wild-type littermates (Selman et al., 
2009), perhaps because loss of S6K1 
mimics some aspects of CR. These mice 
are lean and sensitized to insulin because 
of a decrease in the phosphorylation of 
threonine residues in IRS1 (insulin recep-
tor substrate 1) resulting in altered insu-
lin signaling (Um et al., 2004). Based on 
gene expression data and the character-
ization of worms carrying mutant S6K1 
and AMPK, it seems that the beneficial 
effects of the loss of S6K1 on glucose 
homeostasis and life span are principally 
mediated through AMPK activation (Sel-
man et al., 2009).
Sirtuins are a class of NAD+-depen-
dent deacetylases, which deacetylate 
both histones and a wide range of pro-
teins (Houtkooper et al., 2010). The con-
nection between sirtuins and longevity is 
based on the discovery that the effects 
of CR on life span are, at least in part, 
mediated by the sirtuin orthologs Sir2/
SIRT1 in yeast, fly, and worm. Although 
the exact function of Sir2/SIRT1 in life-
span extension is still not known, its 
activating effects on mitochondrial res-
Figure 1. A Metabolic Network of Aging
This simplified scheme shows metabolic proteins that are involved in longevity. There are complex inter-
actions among individual metabolic signaling pathways, such as the insulin/IGF1, TOR, AMPK, sirtuin, 
and FOXO pathways. These interactions impact health span and longevity. For instance, the TOR path-
way, which is activated during nutrient excess, is linked not only to other nutrient-responsive pathways, 
such as the insulin/IGF1 pathway, but also to the CR-induced pathway involving AMPK and Foxa activa-
tion. Longevity-promoting proteins are in green, proteins that increase longevity when mutated are in 
orange, and other proteins are indicated in blue; mammalian protein names are used.10 Cell 142, July 9, 2010 ©2010 Elsevier Inc.
piration are thought to play a crucial role 
(Canto and Auwerx, 2009). Consistent 
with the link between SIRT1 function and 
metabolism, single-nucleotide polymor-
phisms in SIRT1 have been associated 
with energy expenditure (Lagouge et al., 
2006) and SIRT1 expression levels are 
tightly correlated with insulin sensitivity 
in humans (Rutanen et al., 2010). Nota-
bly, a recent study showed that trans-
genic mice overexpressing Sirt1 have an 
improved health span and are protected 
against diseases of aging, such as dia-
betes and cancer, but do not show an 
increased life span (Herranz et al., 2010). 
This striking absence of a longevity phe-
notype in Sirt1 transgenic mice under-
scores the pitfalls associated with trans-
lating the conclusions of studies in yeast, 
worm, and flies to mammals. Additional 
data concerning the possible relation of 
SIRT1 and mouse or human longevity 
are eagerly awaited. Finally, a potentially 
interesting association between poly-
morphisms in the SIRT3 gene, one of the 
mitochondrial sirtuins, and longevity was 
reported in a small human study (Bellizzi 
et al., 2005).
Some of the sirtuin longevity path-
ways involved in CR-mediated life-span 
extension, most notably those involv-
ing SIRT1, are tightly intertwined with 
those controlled by the metabolic sensor 
AMPK, which has been linked to longev-
ity in multiple ways. Like the FOXOs, the 
role of AMPK in CR-induced longevity is 
still debated (Kenyon, 2010); however, 
it does seem to be important in several 
longevity pathways. Indeed, the benefi-
cial effect of S6K1 deficiency on life span 
is thought to involve AMPK activation 
(Selman et al., 2009). In addition, AMPK 
phosphorylates and thereby activates 
FOXO, possibly impacting longevity. 
Another mechanism by which AMPK may 
control longevity entails boosting NAD+ 
levels and activating SIRT1, which in turn 
deacetylates and activates targets, such 
as PGC-1α and FOXO1, leading to the 
induction of mitochondrial activity, respi-
ratory metabolism, and oxidative stress 
responses (Canto et al., 2009, 2010). A 
role for AMPK in longevity is also sup-
ported by the fact that metformin, an 
AMPK agonist that is used clinically for 
treating type 2 diabetes, extends life 
span in mice (Anisimov et al., 2008). In 
addition, resveratrol, a drug that acti-
vates SIRT1 but not in a direct fashion 
(Beher et al., 2009; Pacholec et al., 2010), 
achieves this effect by mildly inhibit-
ing mitochondrial respiration, thereby 
inducing energy stress. The subsequent 
increase in the AMP/ATP ratio activates 
AMPK, increases NAD+ levels, and stimu-
lates SIRT1, resulting in a compensatory 
induction of mitochondrial activity (Canto 
et al., 2009, 2010; Um et al., 2010), a pro-
cess termed “mitohormesis.” In mice fed 
a high-calorie diet, resulting in a signifi-
cantly decreased life span, resveratrol 
normalized life span, suggesting that the 
AMPK/SIRT1 pathway is involved (Baur 
et al., 2006). Although this suggests the 
involvement of AMPK/SIRT1 signaling in 
longevity, many aspects—such as the 
role of this signaling pathway and mito-
chondria in CR—remain to be investi-
gated, especially in mammals.
Many of the longevity genes identified 
to date have multiple effects on metab-
olism and appear to be intertwined in 
partly overlapping metabolic signaling 
networks that often affect the function 
of mitochondria (Figure 1). Supporting 
a potential role for mitochondria in lon-
gevity is the fact that activation of the 
transcriptional cofactor PGC-1α, which 
in mammals controls many aspects of 
mitochondrial biogenesis and function, 
protects against diseases associated 
with aging (Baur et al., 2006; Lagouge et 
al., 2006). Definitive proof of PGC-1α’s 
role in longevity is, however, still lacking. 
The impact of certain mutations in mito-
chondrial genes also deserves attention. 
Could it be that mutations that partially 
impair mitochondrial function, such as 
the oxidative phosphorylation or ubiqui-
none synthesis mutants of the worm (Dil-
lin et al., 2002; Lee et al., 2003), induce 
mitohormesis and longevity? The seem-
ingly contradictory results regarding 
activation or inhibition of mitochondrial 
metabolism and increased longevity 
warn us that a simple genetic approach 
is not sufficient and that a more integra-
tive physiological approach, including 
the thorough study of epigenetic and 
metabolic pathways, is warranted. The 
characterization of these pathways will 
undoubtedly be fertile ground for fur-
ther research in the longevity field and 
will result in a clearer view of how mito-
chondria are involved in longevity and in 
aging-related diseases.
Multifactorial Aspects of Longevity
Studies of genetically engineered animal 
models have proven useful for identify-
ing longevity genes, but monogenic 
approaches have limitations. We also 
need methods that make it possible to 
study complex polygenic networks that 
interact with environmental factors to 
influence metabolic homeostasis and 
longevity. A hallmark of such complex 
traits is their graded and nearly continu-
ous distribution throughout a population. 
Single gene variants are not associated 
with clear-cut Mendelian and modal 
patterns of inheritance. However, con-
tributions of these variants can often 
be mapped to specific chromosomal 
regions that are called quantitative trait 
loci (QTLs) because they generate some 
fraction of the total variation of trait val-
ues in study populations. The study of 
complex traits has advanced rapidly and 
has relied on both family linkage studies 
and genome-wide association studies 
of large human cohorts. Corresponding 
studies in model organisms have often 
exploited test crosses (F2 intercrosses 
and backcrosses) and genetic reference 
panels, including sets of congenic and 
recombinant inbred strains. But how are 
these genetic approaches being applied 
to identify genes and molecular networks 
associated with longevity?
Studies of human populations have 
led to the identification of a number of 
loci associated with longevity (de Magal-
haes et al., 2009). These studies gener-
ally entail an analysis of populations with 
exceptionally long life spans, such as 
centenarians. This approach is valuable, 
but studies of humans are still difficult 
because of the limited availability of sub-
jects and potential confounding environ-
mental factors. The most important limi-
tation is of course that prospective and 
experimental perturbations are usually 
not feasible for testing causal models.
Studies of rodents and other model 
organisms overcome some of these 
problems and allow us to add the experi-
mental component while still accounting 
for genetic diversity. The most straight-
forward network approach uses model 
organisms in which a single gene is per-
turbed, either by genetic deletion or RNA 
interference, to map the compensatory 
mechanisms that result in a longevity 
trait. A more complicated method, but Cell 142, July 9, 2010 ©2010 Elsevier Inc. 11
also more realistic in terms of model-
ing longevity, involves the characteriza-
tion of QTLs in recombinant inbred lines. 
Recombinant inbred lines of D. melano-
gaster have been used extensively for 
the identification of QTLs for longev-
ity. These studies typically use ?100 
recombinant inbred fly lines to measure 
life span and link variation to specific 
QTLs (Curtsinger and Khazaeli, 2002). A 
challenge has been to achieve sufficient 
resolution to define responsible gene 
variants. A recent study used extreme 
QTL (X-QTL) mapping to define determi-
nants of mitochondrial function in yeast 
(Ehrenreich et al., 2010). Even though 
this study did not assess yeast replica-
tive or chronological life span, it marks 
an important step because X-QTL analy-
sis allows mapping of not only major 
QTLs but also minor ones that might 
be missed using classical methods. An 
interesting alternative approach involves 
the analysis of modular networks (Xue et 
al., 2007). Combining genes in various 
modules (e.g., differentiation, prolifera-
tion, oxidative metabolism, and reduc-
tive metabolism) reveals that the aging 
process in the fly is characterized by a 
general shift from oxidative to reduc-
tive metabolism. CR clearly slows down 
this shift, thereby accounting for the 
longevity effect. Known aging genes 
are highly represented as “date hubs” 
between these modules, indicating that 
they serve as important regulators of 
aging (Xue et al., 2007). Interestingly, this 
unbiased network approach confirmed 
the importance of oxidative metabolism, 
implicated by monogenic studies.
Another step forward will be the 
switch from relatively simple organisms, 
such as yeast and C. elegans, to more 
complex mammalian systems. Genetic 
and genomic analyses of large mouse 
families, generated by intercrossing 
long-lived and short-lived stock, will be 
useful for finding new longevity genes 
and networks. We recently used gene 
expression data for adipose tissue from 
four large mouse F2 crosses to identify 
candidate longevity networks. Follow-
ing the strategy of using the “known” to 
uncover the “unknown,” we leveraged a 
seed set of 60 known longevity genes 
to extract a larger network, containing 
742 tightly connected longevity genes 
(Argmann et al., 2009). Among the top 
20 genes tightly connected with known 
longevity genes was 4E-BP, a deter-
minant of longevity in multiple species 
(Argmann et al., 2009; Zid et al., 2009). 
When we applied pathway enrichment 
analysis to uncover relationships among 
the 742 genes contained within the lon-
gevity network, we detected enrich-
ment in several gene ontologies with 
established links to aging, such as the 
complement and coagulation cascades 
(inflammation), insulin signaling, and 
the ubiquinone pathway (i.e., oxidative 
stress). Importantly, other unsuspected 
pathways were also highly enriched, 
including PPAR signaling—an ontology 
that actually ranked highest. Using an 
allelic series of PPARγ mutant mice, we 
validated a role for PPARγ in longevity 
(Argmann et al., 2009; Heikkinen et al., 
2009).
The analysis of mouse genetic refer-
ence populations is another powerful 
strategy to identify molecular networks 
that influence longevity. Genetic ref-
erence populations, such as the BXD 
and LXS mouse strains and the HXB rat 
strains, are stable families of inbred lines 
that can be used for large-scale col-
laborative phenotyping across multiple 
dimensions. These types of resources are 
ideal for studying the genetics of longev-
ity because each genome is represented 
by an entire strain, making it possible to 
obtain far more accurate mortality data 
for each cohort of animals and for all 
genotypes under different experimental 
conditions and interventions. The strains 
within a genetic reference population 
collectively incorporate a level of genetic 
variation that can match or exceed that 
of human populations, making them an 
excellent vehicle with which to explore 
the generality of findings, the role of 
genetic background effects, and the 
translational relevance of gene variants 
to human populations and disease.
Two large mouse genetic reference 
populations are now being used actively 
in longevity research—the BXD set 
generated by crossing C57BL/6J and 
DBA/2J, and the LXS set generated by 
crossing ILS/IbgTejJ and ISS/IbgTejJ. 
Using the original subset of BXD strains, 
several regions in the mouse genome 
have been linked to longevity (De Haan 
and Van Zant, 1999; Gelman et al., 1988), 
but small sample sizes and technical 
limitations have hampered the analysis. 
However, larger and much more power-
ful genetic and genomic datasets can 
now be exploited to reanalyze original 
longevity data for larger genetic refer-
ence populations and to extract more 
definitive and precise mapping results. 
Following identification of a QTL, candi-
date genes can be identified by associa-
tion studies between mRNA expression 
and the trait, that is, life span. Expres-
sion of these genes can then also be 
cross-referenced with the expression 
of other genes, allowing a network to 
be assembled. Online tools, such as 
the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) and gene ontology 
(GO) analysis, can help in the identifi-
cation of pathways linked to candidate 
genes. Finally, interesting candidate 
genes can be validated using longevity 
analyses in vivo. The advantage of this 
approach is that it uses natural variations 
in gene expression (like those found in 
normal human populations) instead of 
relying on the more artificial situation that 
occurs in gene knockout or knockdown 
experiments. It is imperative to realize 
that the directionality of the association 
cannot be identified using such strate-
gies and that additional physiological 
evidence is always required to back up 
the genetic data and establish causal-
ity and directionality. This is especially 
relevant as various longevity pathways 
obtained in lower organisms proved dif-
ficult to phenocopy in mammals (Russell 
and Kahn, 2007), and in other cases, 
mutations in the same gene resulted in 
opposite effects on life span (Argmann et 
al., 2009; Heikkinen et al., 2009). These 
discrepancies indicate that additional 
efforts should be put into the identifica-
tion of the mechanisms underlying these 
differences, and attention should be paid 
not only to genetic but also to epigenetic 
factors that could affect metabolic net-
works of aging.
Perspectives
Studies using single-gene gain or loss 
to alter gene activity in various organ-
isms, ranging from yeast to mouse, have 
provided a wealth of information about 
specific genes, such as those encoding 
components of the insulin/IGF1 pathway, 
involved in longevity. Using such reduc-
tionist approaches, an emerging theme 12 Cell 142, July 9, 2010 ©2010 Elsevier Inc.
is the overrepresentation of metabolic 
pathways in general, and of mitochon-
drial activity in particular, as determi-
nants of longevity. In this Essay, we have 
outlined the known metabolic pathways 
impacting longevity and we have inte-
grated these pathways in a simplified 
network (Figure 1).
Although it has long been appreci-
ated that longevity is a complex process 
influenced by multiple gene variants, 
the development of complex genetics, 
genomics, and bioinformatics tools is 
now finally enabling a more thorough 
systems analysis of longevity networks. 
By using population studies in mouse 
and human, multiple genes and path-
ways have been recently linked to lon-
gevity and aging-related diseases. We 
have tried to give a flavor of what may 
soon emerge by using such synthetic 
approaches. In the near term, we fore-
see that the continued use of complex 
genetic strategies will gain importance in 
the longevity field and lead to the identi-
fication of tightly regulated longevity net-
works that govern intersecting metabolic 
pathways often affecting mitochondrial 
functions. Furthermore, it will prove 
increasingly important to extend these 
studies beyond a purely genetic level 
to include the evaluation of epigenetic 
factors. Such epigenetic factors impact 
processes ranging from DNA transcrip-
tion (histone and DNA modifications), 
RNA (miRNAs), and protein stability and 
activity (posttranslational modifications), 
to metabolite levels (metabolite ligands 
or cofactors for proteins). The applica-
tion of such holistic research strategies 
to elucidate the mechanisms by which 
CR impacts health span and life span in 
a variety of model organisms will proba-
bly be a major step forward in our under-
standing of the aging process. Finally, 
given the conserved role of mitochon-
dria across species in the determination 
of longevity, obtaining insights into the 
complex and multifactorial regulation of 
metabolic flexibility may in fact hold the 
key to unlock the metabolic underpin-
nings of aging. The importance of meta-
bolic flexibility for longevity is perhaps 
best illustrated by the universal associa-
tion of a shift from glycolytic to oxidative 
metabolism in CR or endurance exercise, 
conditions that improve health span, 
whereas the converse switch from oxi-
dative to glycolytic metabolism occurs 
when health span is compromised, such 
as in cancer or ischemia. It goes without 
saying that identifying the crucial nodes 
of these metabolic longevity networks 
might translate into the development of 
targeted preventative and therapeutic 
strategies to improve health span, a goal 
since the quest of Ponce de Leon to find 
the fountain of youth.
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